|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
|
|
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders.
|
Proposal 1. |
Stockholders voted as follows with respect to the election of each of the nominees for director identified in the proxy statement:
|
Nominee
|
For
|
Withhold
|
Broker Non-Votes
|
David W.K. Acheson
|
6,001,479
|
1,811,952
|
8,472,928
|
David W. Bespalko
|
5,992,539
|
1,820,892
|
8,472,928
|
Katherine L. Davis
|
5,809,292
|
2,004,139
|
8,472,928
|
Richard L. Eberly
|
5,944,476
|
1,868,955
|
8,472,928
|
John G. Potthoff
|
5,793,758
|
2,019,673
|
8,472,928
|
Leslie Teso-Lichtman
|
6,292,054
|
1,521,377
|
8,472,928
|
Proposal 2. |
Stockholders ratified the appointment of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2022, by the following vote:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
Ratification of appointment of Ernst & Young LLP
|
14,463,390
|
1,611,817
|
211,152
|
—
|
Proposal 3. |
Stockholders approved, on a non-binding advisory basis, the compensation paid to our executive officers in 2021, as disclosed in the 2022 proxy statement, by the following vote:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
Advisory vote on 2021 executive compensation
|
5,133,676
|
2,349,756
|
329,997
|
8,472,930
|
Chembio Diagnostics, Inc.
|
||
Dated: May 26, 2022
|
By:
|
/s/ Lawrence J. Steenvoorden
|
Executive Vice President and Chief Financial Officer
|